IDH 305

Drug Profile

IDH 305

Alternative Names: IDH305

Latest Information Update: 27 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Novartis; Novartis Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 16 Jan 2018 Novartis withdraws a phase I clinical trial in Acute myeloid leukaemia (First-line therapy) prior to enrolment in Australia (PO) (NCT02826642)
  • 20 Dec 2017 Novartis and New York University School of Medicine withdraws a phase II trial in Glioma prior to enrolment, in USA due to safety evaluation of IDH 305 compound (NCT02977689)
  • 11 Oct 2017 University of Texas Southwestern Medical Center withdraws a phase II trial for Glioma (Neoadjuvant therapy, Inoperable/Unresectable) prior to enrolment in USA, as sponsor did not want to move forward with the protocol (PO) (NCT02987010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top